ScreenerHero

SLNSilence Therapeutics plc

NAS · US · Healthcare · Biotechnology · silence-therapeutics.com
13.27USDMkt Cap: 824.78M $P/E: —

Silence Therapeutics plc, a biotechnology company, engages in the discovery and development of novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes i…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap824.78M $
Enterprise Value571.09M $
Revenue (TTM)615.00K $
Gross Profit344.00K $
Net Income (TTM)-88.61M $
Revenue/Share0.0130 USD
Last Price13.27 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees88
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-17.22
PEG—
EV/EBITDA-8.93
EV/Revenue928.59
P/S1331.01
P/B9.98
EPS (TTM)-1.25
EPS (Forward)-0.77
52W Range
13.1340% of range13.48
52W High13.48 USD
52W Low13.13 USD
Profitability
Gross Margin61.54%
Oper. Margin-10475.61%
EBITDA Margin0.00%
Profit Margin-15851.88%
ROE-142.23%
ROA-67.42%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-62.27M $
CapEx (TTM)55.00K $
FCF Margin-3832.13%
FCF Yield-2.86%
Net Debt-71.94M $
Net Debt/EBITDA1.13
Balance Sheet
Debt/Equity0.00
Current Ratio7.42
Quick Ratio6.40
Book Value/Sh1.319 USD
Cash/Share1.525 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.7 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)33.00 USD
Upside (mean)+148.7%
Target Range10.00 USD – 75.00 USD
$10.00+148.7% to mean$75.00
# Analysts6
Ownership
Shares Out.62.15M
Float35.25M
Insiders7.97%
Institutions38.33%
Short Interest
Short Ratio3.4d
Short % Float5.15%
Short % Out.3.89%
Shares Short1.84M
Short (prev mo.)1.73M
Technical
SMA 5010.46 (+26.8%)
SMA 2007.246 (+83.1%)
Beta1.41
S&P 52W Chg21.00%
Avg Vol (30d)734.61K
Avg Vol (10d)3.26M
Technical Indicators
RSI (14)56.6
MACD0.8993
MACD Signal0.9831
MACD Hist.-0.0838
BB Upper15.61 USD
BB Middle12.70 USD
BB Lower9.789 USD
BB Width45.81%
ATR (14)1.051 USD
Vol Ratio (20d)0.38x